Page 467 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Wong 208 SEER- Active 1991-1999 44,630 Patients aged 65 to 80 yr, with Median age: observation, 72.9 B
2006 Medicare treatment incident prostate cancer, stage yr [IQR=69-77 yr]; active
17164454 vs. 12 yr T1/2. Patients were excluded if treatment, 71.0 yr [IQR=68-74
observation followup diagnosis was made at autopsy yr]
Retrospective (a secondary or death or if they had Medicare
cohort analysis entitlement based on end-stage PSA: NR
comparing renal disease; were enrolled in a
radiation Tx managed care plan from 3 mo Observation: well-dif., 25.87%;
and RP, before diagnosis to 6 mo after moderately dif., 64.13%. Active
separately, diagnosis; those with T3/4 treatment, well-dif., 14.29%;
with disease, poorly differentiated or moderately dif., 85.71%
observation anaplastic tumors or metastatic
was also disease, unknown tumor size; Observation: ≤T2a, 55.03%;
reported) current reason for Medicare T2b/c, 44.97%; active
entitlement listed as disability or treatment, ≤T2a, 37.92%;
Medicare status were excluded. T2b/c, 62.08%
Patients who received ADT
alone were excluded.

C-151